Septerna (NASDAQ:SEPN) Stock Price Down 4.4% – What’s Next?

Septerna, Inc. (NASDAQ:SEPN) traded down 4.4% during mid-day trading on Friday . The stock traded as low as $22.37 and last traded at $22.37. 17,651 shares were traded during trading, a decline of 93% from the average session volume of 235,892 shares. The stock had previously closed at $23.40.

Wall Street Analysts Forecast Growth

SEPN has been the subject of several research analyst reports. JPMorgan Chase & Co. started coverage on Septerna in a research note on Tuesday, November 19th. They issued an “overweight” rating and a $38.00 price objective for the company. TD Cowen started coverage on Septerna in a report on Tuesday, November 19th. They set a “buy” rating on the stock. Wells Fargo & Company started coverage on shares of Septerna in a report on Tuesday, November 19th. They set an “overweight” rating and a $43.00 price objective for the company. Finally, Cantor Fitzgerald started coverage on Septerna in a research report on Tuesday, November 19th. They issued an “overweight” rating and a $50.00 price target on the stock.

Septerna Trading Up 0.1 %

Insider Transactions at Septerna

In other news, major shareholder Rock Ventures V. L.P. Third bought 370,500 shares of the business’s stock in a transaction that occurred on Monday, October 28th. The stock was acquired at an average cost of $18.00 per share, for a total transaction of $6,669,000.00. Following the purchase, the insider now owns 6,215,591 shares of the company’s stock, valued at approximately $111,880,638. This trade represents a 6.34 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.